CN105188716B - 钙通量激动剂及其方法 - Google Patents

钙通量激动剂及其方法 Download PDF

Info

Publication number
CN105188716B
CN105188716B CN201380070113.2A CN201380070113A CN105188716B CN 105188716 B CN105188716 B CN 105188716B CN 201380070113 A CN201380070113 A CN 201380070113A CN 105188716 B CN105188716 B CN 105188716B
Authority
CN
China
Prior art keywords
calcium
calcium flux
flux agonist
ionophore
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380070113.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105188716A (zh
Inventor
K.尼亚兹
S.拉比扎德
J.戈罗瓦托
P.宋-雄
A-L.勒尼
O.布兹科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nant Holdings IP LLC
Original Assignee
Nant Holdings IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings IP LLC filed Critical Nant Holdings IP LLC
Publication of CN105188716A publication Critical patent/CN105188716A/zh
Application granted granted Critical
Publication of CN105188716B publication Critical patent/CN105188716B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201380070113.2A 2012-11-13 2013-11-13 钙通量激动剂及其方法 Active CN105188716B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725881P 2012-11-13 2012-11-13
US61/725881 2012-11-13
PCT/US2013/069939 WO2014078447A1 (en) 2012-11-13 2013-11-13 Calcium flux agonists and methods therefor

Publications (2)

Publication Number Publication Date
CN105188716A CN105188716A (zh) 2015-12-23
CN105188716B true CN105188716B (zh) 2019-02-22

Family

ID=50731660

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380070113.2A Active CN105188716B (zh) 2012-11-13 2013-11-13 钙通量激动剂及其方法

Country Status (8)

Country Link
US (3) US9463184B2 (enExample)
EP (1) EP2919793B1 (enExample)
JP (2) JP6280129B2 (enExample)
KR (3) KR20150140625A (enExample)
CN (1) CN105188716B (enExample)
AU (1) AU2013344879B2 (enExample)
CA (1) CA2893276C (enExample)
WO (1) WO2014078447A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013344879B2 (en) * 2012-11-13 2016-04-28 Nant Holdings Ip, Llc Calcium flux agonists and methods therefor
CN113144197A (zh) * 2013-02-08 2021-07-23 罗达制药公司 治疗局部微生物感染的方法
US9884087B1 (en) * 2013-05-03 2018-02-06 Chan Soon-Shiong Nanthealth Foundation Compositions and methods of improved wound healing
US10105305B2 (en) * 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
CN108700566A (zh) * 2016-02-19 2018-10-23 河谷控股Ip有限责任公司 免疫原性调节的方法
JP6595746B2 (ja) * 2016-09-19 2019-10-23 フラー・ラボラトリーズ バベシア・ミクロチのインビトロ増殖
CN107496420B (zh) * 2017-08-25 2020-07-07 中国科学院微生物研究所 环匹阿尼酸类生物碱化合物的用途
US11969402B2 (en) 2019-05-16 2024-04-30 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN111840560B (zh) * 2020-07-24 2021-09-03 广州医科大学 钙离子载体在白癜风治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960667A (en) 1972-03-23 1976-06-01 Eli Lilly And Company Antibiotic A23187 and process for preparation thereof
US3873693A (en) 1974-03-11 1975-03-25 Squibb & Sons Inc Ionomycin
US5489441A (en) * 1992-01-07 1996-02-06 Procept, Inc. Method for suppressing immune response associated with psoriasis, contact dermatitis and diabetes mellitus
US5238689A (en) * 1992-01-07 1993-08-24 Procept, Inc. Use of ruthenium red as immunosuppressive agents
TWI268153B (en) * 2004-06-23 2006-12-11 Univ Nat Cheng Kung A medicine composition for increasing leukocyte immunity wherein a leukocyte treated by sarcoplasmic/endoplasmic reticulum Ca2+ ATPase
GB0505909D0 (en) * 2005-03-23 2005-04-27 Univ Leeds Formulations
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
US20080160116A1 (en) * 2006-12-07 2008-07-03 Herbalscience Singapore Pte. Ltd Compositions and Methods Comprising Zingiber Species
US20100105644A1 (en) * 2008-10-27 2010-04-29 The Regents Of The University Of Michigan Botanical composition for enhanced skin repair and uses thereof
CA2783244A1 (en) 2009-12-07 2011-06-16 Momentum Technologies, Inc. Nutrient yielding bio-renewable controlled release fertilizer coatings
WO2011115970A1 (en) 2010-03-15 2011-09-22 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
WO2012054792A2 (en) * 2010-10-22 2012-04-26 Virginia Commonwealth University Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
AU2013344879B2 (en) * 2012-11-13 2016-04-28 Nant Holdings Ip, Llc Calcium flux agonists and methods therefor

Also Published As

Publication number Publication date
JP2015537000A (ja) 2015-12-24
JP6280129B2 (ja) 2018-02-14
WO2014078447A1 (en) 2014-05-22
KR20150140625A (ko) 2015-12-16
EP2919793B1 (en) 2020-05-06
JP6625677B2 (ja) 2019-12-25
EP2919793A4 (en) 2016-06-01
US20170128568A1 (en) 2017-05-11
US20150297572A1 (en) 2015-10-22
KR20190038679A (ko) 2019-04-08
US9750805B2 (en) 2017-09-05
KR20170126031A (ko) 2017-11-15
AU2013344879B2 (en) 2016-04-28
CN105188716A (zh) 2015-12-23
US20170360925A1 (en) 2017-12-21
CA2893276C (en) 2017-04-18
EP2919793A1 (en) 2015-09-23
CA2893276A1 (en) 2014-05-22
JP2018080199A (ja) 2018-05-24
US9463184B2 (en) 2016-10-11

Similar Documents

Publication Publication Date Title
CN105188716B (zh) 钙通量激动剂及其方法
Oršolić et al. Immunomodulation by water-soluble derivative of propolis: a factor of antitumor reactivity
JP6944399B2 (ja) プロバイオティクス細菌
Qin et al. Nitric oxide–releasing nanoparticles prevent Propionibacterium acnes–induced inflammation by both clearing the organism and inhibiting microbial stimulation of the innate immune response
AU2013344879A1 (en) Calcium flux agonists and methods therefor
Hu et al. Gut microbiota mediate the protective effects on endometritis induced by Staphylococcus aureus in mice
EA035091B1 (ru) Смесь жирных кислот (гжк, группа жирных кислот) и её применение для лечения воспалительных патологий
Yusuf et al. Surface modification of silver nanoparticle (AgNP) by liposomal encapsulation mitigates AgNP-induced inflammation
DE3887686T2 (de) Bakterielle zubereitung für die prophylaxe und behandlung von entzuendungen und allergischen beschwerden.
CN116650557B (zh) 一种抗菌消炎剂、敷料及其制备方法
CN103249419B (zh) 具有抗菌和创伤愈合活性的组合物
Hu et al. The ROS-responsive FA@ Ni@ HA hydrogel promotes infected wound healing in DIO mice through endogenous antimicrobial peptides and macrophage recruitment
Molanaei et al. Evaluation of the sensitivity of Staphylococcus aureus isolated from nasal swabs to natural honey
Moura et al. Down‐Regulatory Effect of Mycobacterium leprae Cell Wall Lipids on Phagocytosis, Oxidative Respiratory Burst and Tumour Cell Killing by Mouse Bone Marrow Derived Macrophages
RU2657785C1 (ru) Композиция для интравагинального введения
RU2693228C2 (ru) Композит для ускоренного заживления ран различной этиологии, применение композита в качестве косметического средства и в качестве лечебного средства в ветеринарии, средство для регенерации кожных покровов на основе композита
CN110946862A (zh) 血根碱在抑制多重耐药霍氏肠杆菌生长中的应用
CN113491740B (zh) 一种防治白色念珠菌病的组合物及含有该组合物的药物和饲料添加剂
RU2698201C1 (ru) Разработка противогрибковой мази на основе сальвина
KR20120086123A (ko) 항균성 피부 외용제 조성물
Jin et al. Both live and heat-killed Bifidobacterium animalis J-12 alleviated oral ulcer of LVG golden Syrian hamsters by intervening intestinal flora structure
CA2425025C (en) Use of bioactive fraction from cow urine distillate ('go mutra') as a bio-enhancer of anti-infective, anti-cancer agents and nutrients
CN116850171A (zh) 饱和脂肪酸在制备治疗细菌感染性疾病的药物或抗生素增效剂中的应用
WO2021076020A2 (ru) Фармацевтическая композиция для лечения и профилактики инфекционно-воспалительных заболеваний
KR20200133032A (ko) 메틸 갈레이트 및 플로로퀴놀론 계열 항균제를 포함하는 박테리아의 장 부착, 침입 억제, 또는 항생제 내성 억제용 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant